Study on Using Raman Spectroscopy to Diagnose Kidney Diseases Including IgA Nephropathy, Membranous Nephropathy, Diabetic Nephropathy, and Focal Segmental Glomerulosclerosis

What this Trial Is About

Researchers are studying patients with specific kidney diseases including IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy, and focal segmental glomerulosclerosis. The goal is to develop a non-invasive and efficient diagnostic method using Raman spectroscopy combined with statistical analysis. This approach aims to assist in diagnosing these kidney diseases and predicting treatment outcomes based on data collected from renal biopsy-confirmed patients. The study involves collecting serum and morning urine samples from patients, which are then analyzed using Raman spectroscopy to obtain spectral data. The data is processed to identify chemical bonds and quantify analyte concentrations. Statistical methods like principal component analysis and Mahalanobis distance discriminant modeling are used to classify and predict disease types. This is an observational study with no experimental treatment. Participants provide blood and urine samples within two days of enrollment, which are scanned using Raman spectroscopy. Researchers analyze the spectral images to measure chemical substance peaks and concentration levels. The primary outcome is the quality and interpretation of these Raman spectroscopy images. The study runs from February 2021 through July 2025, with all data collection completed within a short time frame after enrollment.

Raman Spectroscopy Diagnosis of Kidney Diseases